Isotrace Technologies Report issue

For profit Phase 1
Founded: O'Fallon MO United States (2004)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2009
NCT00968656
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

18f iso (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 1)

Hyperplasia (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1